348 related articles for article (PubMed ID: 17379101)
1. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
3. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
5. Novel biological therapies for the treatment of multiple myeloma.
Richardson PG; Mitsiades CS; Hideshima T; Anderson KC
Best Pract Res Clin Haematol; 2005; 18(4):619-34. PubMed ID: 16026741
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
[TBL] [Abstract][Full Text] [Related]
7. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
8. Oncogenomics to target myeloma in the bone marrow microenvironment.
Anderson KC
Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
[TBL] [Abstract][Full Text] [Related]
9. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
10. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
11. The malignant clone and the bone-marrow environment.
Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
13. [Management of multiple myeloma].
Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
16. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: thalidomide as a treatment for multiple myeloma.
Kumar S; Anderson KC
Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
19. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
